Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens

Vaccine

Volumn 28, Issue 11, 2010, Pages 2311-2317

  Shim, Doo Hee ^a   Ko, Hyun Jeong ^a   Volker, Gerdts ^b   Potter, Andrew A ^b   Mutwiri, George ^b   Babiuk, Lorne A ^c   Kweon, Mi Na ^a  

^a International Vaccine Institute   (South Korea)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adjuvant; Infectious diseases; Intranasal; Mucosal immunity; Polyphosphazene

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MEMBRANE PROTEIN; PERTUSSIS TOXIN; PERTUSSIS TOXOID; PNEUMOCOCCAL SURFACE PROTEIN A; POLY[DI(SODIUM CARBOXYLATOPHENOXY)PHOSPHAZENE]; PR8 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCING CELL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS; MONONUCLEAR CELL; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE SECRETION; PERTUSSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SALIVA; TH1 CELL; TH2 CELL; TRACHEOBRONCHIAL TOILET; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; ORTHOMYXOVIRIDAE INFECTIONS; PERTUSSIS VACCINE; PHENYLPROPIONATES; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; POLYMERS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME; WHOOPING COUGH;

EID: 77049112961     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.069     Document Type: Article

References (34)

1. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 4 Suppl. (2005) S45-53
2. Brandtzaeg P., and Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol 25 11 (2004) 570-577
3. Kweon M.N., Fujihashi K., Wakatsuki Y., Koga T., Yamamoto M., McGhee J.R., et al. Mucosally induced systemic T cell unresponsiveness to ovalbumin requires CD40 ligand-CD40 interactions. J Immunol 162 4 (1999) 1904-1909
4. Yuki Y., and Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 13 5 (2003) 293-310
5. Singh M., and O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 17 11 (1999) 1075-1081
6. Lycke N. The mechanism of cholera toxin adjuvanticity. Res Immunol 148 8-9 (1997) 504-520
7. Xu-Amano J., Kiyono H., Jackson R.J., Staats H.F., Fujihashi K., Burrows P.D., et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 178 4 (1993) 1309-1320
8. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's Palsy in Switzerland. N Engl J Med 350 9 (2004) 896-903
9. van Ginkel F.W., Jackson R.J., Yuki Y., and McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165 9 (2000) 4778-4782
10. Eriksson A.M., Schon K.M., and Lycke N.Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 173 5 (2004) 3310-3319
11. Kweon M.N., Yamamoto M., Watanabe F., Tamura S., Van Ginkel F.W., Miyauchi A., et al. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis 186 9 (2002) 1261-1269
12. Lu X., Clements J.D., and Katz J.M. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 20 7-8 (2002) 1019-1029
13. Yamamoto S., Kiyono H., Yamamoto M., Imaoka K., Fujihashi K., Van Ginkel F.W., et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 94 10 (1997) 5267-5272
14. + T cells producing IFN-gamma and IL-10. J Invest Dermatol 129 8 (2009) 1963-1971
15. Guiducci C., Ott G., Chan J.H., Damon E., Calacsan C., Matray T., et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 203 8 (2006) 1999-2008
16. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 74 1 (2006) 694-702
17. Andrianov A.K., and Payne L.G. Polymeric carriers for oral uptake of microparticulates. Adv Drug Deliv Rev 34 2-3 (1998) 155-170
18. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16 1 (1998) 92-98
19. Andrianov A.K., Marin A., and Chen J. Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene]. Biomacromolecules 7 1 (2006) 394-399
20. McNeal M.M., Rae M.N., and Ward R.L. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17 11-12 (1999) 1573-1580
21. Mutwiri G., Benjamin P., Soita H., Townsend H., Yost R., Roberts B., et al. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25 7 (2007) 1204-1213
22. Mutwiri G., Benjamin P., Soita H., and Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 26 22 (2008) 2680-2688
23. Shim D.H., Chang S.Y., Park S.M., Jang H., Carbis R., Czerkinsky C., et al. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a. Vaccine 25 25 (2007) 4828-4836
24. Mielcarek N., Debrie A.S., Raze D., Bertout J., Rouanet C., Younes A.B., et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2 7 (2006) e65
25. Park S.M., Ko H.J., Shim D.H., Yang J.Y., Park Y.H., Curtiss III R., et al. MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen. J Immunol 181 9 (2008) 6447-6455
26. Song J.-H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.-Y., Park S.-H., et al. From the cover: sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 105 5 (2008) 1644-1649
27. Duverger A., Jackson R.J., van Ginkel F.W., Fischer R., Tafaro A., Leppla S.H., et al. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 176 3 (2006) 1776-1783
28. + T cells for key functions other than specific antibody production. J Exp Med 191 11 (2000) 1841-1852
29. Mozdzanowska K., Maiese K., and Gerhard W. Th cell-deficient mice control influenza virus infection more effectively than Th- and B cell-deficient mice: evidence for a Th-independent contribution by B cells to virus clearance. J Immunol 164 5 (2000) 2635-2643
30. Roche A.M., King S.J., and Weiser J.N. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect Immun 75 5 (2007) 2469-2475
31. Macpherson A.J., McCoy K.D., Johansen F.E., and Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 1 1 (2008) 11-22
32. Andrianov A.K., Marin A., and Roberts B.E. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 6 3 (2005) 1375-1379
33. Payne L.G., and Andrianov A.K. Protein release from polyphosphazene matrices. Adv Drug Deliv Rev 31 3 (1998) 185-196
34. Mapletoft J.W., Oumouna M., Kovacs-Nolan J., Latimer L., Mutwiri G., Babiuk L.A., et al. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 89 Pt 1 (2008) 250-260